WuXi Biologics (Cayman) Inc.
2269
Classifica tra le azioni
#991
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Prezzo delle azioni
$5.74
Capitalizzazione di mercato
$23.64B
Variazione (1 giorno)
-8.79%
Variazione (1 anno)
24.58%
Paese
CN
Scambia WuXi Biologics (Cayman) Inc. (2269)
Categoria
Healthcare
Utile per WuXi Biologics (Cayman) Inc. (2269)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di WuXi Biologics (Cayman) Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di WuXi Biologics (Cayman) Inc. dal 2014 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2025 | $1.04B | 56.60% |
| 2024 | $662.33M | 12.33% |
| 2023 | $589.64M | -24.09% |
| 2022 | $776.72M | 23.63% |
| 2021 | $628.25M | 108.78% |
| 2020 | $300.91M | 85.98% |
| 2019 | $161.80M | 50.86% |
| 2018 | $107.25M | 129.77% |
| 2017 | $46.68M | 84.29% |
| 2016 | $25.33M | 151.48% |
| 2015 | $10.07M | 27.28% |
| 2014 | $7.91M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
